Entasis Therapeutics Expands Executive Leadership Team with the Appointment of Anna Diaz Triola as Chief Commercial Officer
Retrieved on:
Wednesday, July 14, 2021
WALTHAM, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the appointment of Anna Diaz Triola as Chief Commercial Officer, effective July 19th 2021.
Key Points:
- WALTHAM, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today the appointment of Anna Diaz Triola as Chief Commercial Officer, effective July 19th 2021.
- Ms. Triola will be responsible for global commercial strategy, including U.S. sales and marketing operations.
- Anna brings a distinctive set of commercial and leadership skills to Entasis, and a track record of commercializing products across multiple therapeutic areas, including antibacterials.
- Prior to joining Summit, Ms. Triola held commercial leadership roles at Flexion Therapeutics, Chiasma, Cubist, and Biogen.